Standard titration protocol from clinical trials The Phase 2 NEJM trial used the following escalation schedule for the 12 mg dose group: Weeks 1 through 4: 2 mg once weekly (subcutaneous) Weeks 5 through 8: 4 mg once weekly Weeks 9 through 12: 8 mg once weekly Week 13 and beyond: 12 mg once weekly (maintenance dose) For the 8 mg target dose, the schedule was: Weeks 1 through 4: 2 mg once weekly Weeks 5 through 8: 4 mg once weekly Week 9 and beyond: 8 mg once weekly (maintenance dose) These titration schedules are not suggestions
Standardized tissue injuries were introduced, and comparative outcomes were assessed over a defined observation period
Alcoholism, malabsorption, prolonged stress, tapeworm infestation, vegan diets, celiac, hyperthyroidism, hepatic-biliary tract disease, persistent diarrhea, ileal resection, pancreatic cancer, renal disease, macrobiotic diets or other restrictive diets
Peptides that need acetic acid water GHK-Cu is the most common case